Peripheral blood progenitor cell transplantation: Where do we stand?
Open Access
- 1 April 1996
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 7 (suppl_2) , 1-4
- https://doi.org/10.1093/annonc/7.suppl_2.1
Abstract
Whether or not peripheral stem cells have an unlimited capacity for self renewal is debated. However, everyday haematopoietic requirements are met by progenitors; and it seems that few ‘real’ stem cells are needed. Although we may not yet have identified these ‘true’ stem cells, for practical purposes the long term culture-initiating cells (LTC-ICs) are a close approximation. To date, experience in peripheral blood progenitor cell (PBPC) transplantation is largely con fined to non-ablative regimens. It is therefore difficult to determine the number of PBPCs needed to effect long-term reconstitution. The number of tumour cells present among mobilised PBPCs can be reduced using the CD34 affinity colunm and by positive purging methods. The ex vivo expansion of CD34 cells also has the effect of diluting tumour cell concentration. In clinical use, PBPC transplantation has a proven role in support of high dose chemotherapy in certain haematological and oncological malignancies but the concept of dose intensification is not universally accepted. With the exception of leukaemia, lymphoma, myeloma or relapsed testicular cancer and possibly some subgroups of breast cancer, high dose chemotherapy does not demonstrate a survival benefit. For patients with CMT., autografting with Ph - cells appears to become a useful alternative to allogeneic BMT. Allogeneic PBPC transplantation may have potential, though work is preliminary. Cord blood transplantation between matched siblings is viable, but it is not yet clear whether this source will increase the donor pool for adults needing allogeneic transplantation. For gene therapy using haematopoietic cells to be effective, a greatly increased rate of transduction will be needed. Meeting in Paris in September 1996, a European School of Oncology Task Force considered a number of important questions relating to peripheral blood progenitor cell (PBPC) physiology and transplantation. This review is a brief account of their conclusions.Keywords
This publication has 13 references indexed in Scilit:
- Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitutionAnnals of Hematology, 1995
- Reconstitution of Hematopoiesis after High-Dose Chemotherapy by Autologous Progenitor Cells Generated ex VivoNew England Journal of Medicine, 1995
- Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age.Proceedings of the National Academy of Sciences, 1994
- Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma.Journal of Clinical Oncology, 1994
- Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments]Blood, 1994
- Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietinBlood, 1993
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Ex VivoExpansion and Gene Therapy Using Cord Blood CD34+CellsJournal of Hematotherapy, 1993
- Human hematopoietic stem cell adherence to cytokines and matrix molecules.Journal of Clinical Investigation, 1992
- Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers.Proceedings of the National Academy of Sciences, 1990